Market News AIOpen the app

RTSN stock news · Retension Pharmaceuticals, Inc.

Stories about Retension Pharmaceuticals, Inc. (RTSN) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for RTSN

Follow Retension Pharmaceuticals, Inc. (RTSN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RTSN
Free on the App Store and Google Play, or on the web.
  1. Nov 18, 2026, 8:12 AM ET · Market

    Retension Pharmaceuticals shared its third quarter results and updates on its RTN-001 clinical trial.

    Neutral

    Retension's October IPO raised $45.1 million after costs to support its trial. It also issued 4.3 million shares, and trial results remain pending, leaving the outlook unchanged.